StockData
Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc. (RANI) stock

RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3039% above fair value
$0.54+0.01 (+2.66%)

Close on Nov 16, 2026Market cap $75.32MP/E –Yield –

Rani Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Rani Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $18.31M, down 26.9% year over year. For fiscal 2025 it was $20.21M, down 24.3% from the year before. The highest annual figure on record is $39.62M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$20.21M-24.3%
FY2024Dec 31, 2024$26.68M-32.7%
FY2023Dec 31, 2023$39.62M+8.2%
FY2022Dec 31, 2022$36.61M+38.2%
FY2021Dec 31, 2021$26.48M+119.9%
FY2020Dec 31, 2020$12.04M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.02M-8.9%
Q1 FY2026Mar 31, 2026$5.16M-21.4%
Q4 FY2025Dec 31, 2025$4.91M-27.9%
Q3 FY2025Sep 30, 2025$3.22M-47.8%
Q2 FY2025Jun 30, 2025$5.51M-10.0%
Q1 FY2025Mar 31, 2025$6.57M-13.4%
Q4 FY2024Dec 31, 2024$6.81M-10.5%
Q3 FY2024Sep 30, 2024$6.17M-45.0%
Q2 FY2024Jun 30, 2024$6.12M-44.8%
Q1 FY2024Mar 31, 2024$7.59M-21.9%
Q4 FY2023Dec 31, 2023$7.61M-26.8%
Q3 FY2023Sep 30, 2023$11.22M+23.3%
Q2 FY2023Jun 30, 2023$11.09M+16.4%
Q1 FY2023Mar 31, 2023$9.71M+27.9%
Q4 FY2022Dec 31, 2022$10.39M+40.0%
Q3 FY2022Sep 30, 2022$9.10M-23.9%
Q2 FY2022Jun 30, 2022$9.53M+153.5%
Q1 FY2022Mar 31, 2022$7.59M+126.8%
Q4 FY2021Dec 31, 2021$7.42M+122.3%
Q3 FY2021Sep 30, 2021$11.96M+472.2%
Q2 FY2021Jun 30, 2021$3.76M+47.0%
Q1 FY2021Mar 31, 2021$3.35M–
Q4 FY2020Dec 31, 2020$3.34M–
Q3 FY2020Sep 30, 2020$2.09M–
Q2 FY2020Jun 30, 2020$2.56M–

More Rani Therapeutics figures

See a number that looks wrong?